Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine.
Nat Commun
; 13(1): 1971, 2022 04 13.
Article
in English
| MEDLINE | ID: covidwho-1788288
ABSTRACT
Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a "fresh" booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12-14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16-18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI 2.7 to 5.2) in the booster group.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
BNT162 Vaccine
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Adolescent
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Nat Commun
Journal subject:
Biology
/
Science
Year:
2022
Document Type:
Article
Affiliation country:
S41467-022-29578-w
Similar
MEDLINE
...
LILACS
LIS